Gene

TP53

tumor protein p53

Explore in graph →CI-GENE-00035913HGNC:11998 ENSG00000141510 NCBI 7157 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (408)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–50 of 408 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ATM Mutation + CSF2RB Mutation + NTRK1 Mutation + PIK3CB Mutation + PIK3R1 Mutation + TP53 MutationATM TP53 PIK3R1 PIK3CB NTRK1 CSF2RB

Cohorts

Alteration frequency by cohort (200)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved200 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022) brca_mapk_hp_msk_2021	Invasive Breast Carcinoma	Ssm

Literature

Linked publications (58)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 58 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
· Blood · 2016 · PMID 26837699 · validated civic_curation pubmed
TP53 mutation and survival in chronic lymphocytic leukemia.
· J Clin Oncol · 2010 · PMID 20697090 · validated civic_curation pubmed
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
· Leukemia · 2015 · PMID 24943832 · validated civic_curation pubmed
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
· J Clin Oncol · 2017 · PMID 28453411 · validated

TP53 ALTERATION3
(prognostic)	Malignant Ovarian Neoplasm	Prognostic	B	Supports Poor Outcome	4	accepted	EID3014 In a study of invasive ovarian carcinoma patients who had undergone surgery, the p53 alteration variant was defined as p53 mutation or p53 overexpression by immunostain (>10% positive). Patients with … (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic
〃	Rhabdomyosarcoma	Prognostic	B	Supports Poor Outcome	4	accepted	EID9594 This study evaluated 641 cases of rhabdomyosarcoma (RMS) that were enrolled in the Children’s Oncology Group (COG) trials from 1998 to 2017 and the UK malignant mesenchymal tumor and RMS2005 trails fr… (full text at CIViC) PMID 34166060 · Shern et al., 2021 · Open in CIViC	civic
Carboplatin + CisplatinSubstitutes	Malignant Ovarian Neoplasm	Predictive	B	Supports Resistance	4	accepted	EID2771 In a group of patients with invasive ovarian carcinoma who had undergone surgery, a subset of 74 patients treated with platinum based chemotherapy were assessed for p53 alteration (p53 mutation or p5… (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic

TP53 C135F5
(functional)	—UNRESOLVED	Functional	D	Does Not Support Dominant Negative	3	submitted	EID10588 Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant C135F. Should the mutant be dominant-negative (DN), TP53 will not bind and transactivate the ADE2 protein, resulting in red/p… (full text at CIViC) PMID 10519380 · Marutani et al., 1999 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Loss Of Function	2	submitted	EID9440 Fifty missense mutations identified in sporadic breast cancer were assessed for qualitative and quantitative changes in their ability to transactivate from 11 human promoter response elements in a yea… (full text at CIViC) PMID 20407015 · Jordan et al., 2010 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	E	Supports Loss Of Function	3	submitted	EID7334 Researchers induced sarcoma via radiation and studied the transactivation properties of different induced variants of TP53. As seen in figure 2, the TP53 C135F mutation significantly decreased relativ… (full text at CIViC) PMID 16492679 · Gonin-Laurent et al., 2006 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	E	Supports Loss Of Function	3	submitted	EID7335 The SK-N-BE(2) cell line for neuroblastoma contains a homozygous TP53 C135F mutation. This variant encoded a stable full-length protein that was overexpressed. The variant was shown to have a dominant… (full text at CIViC) PMID 17028100 · Goldschneider et al., 2006 · Open in CIViC	civic
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	submitted	EID10076 A subset of 58 cancer cell lines with unaltered TP53 are sensitive to MDM2 inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 inhibitor.… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic

TP53 C176F2
(functional)	—UNRESOLVED	Functional	D	Does Not Support Dominant Negative	3	submitted	EID10567 Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant C176F originally identified in an oral lesion. Should the mutant be dominant-negative (DN), TP53 will not bind and transactiv… (full text at CIViC) PMID 10519380 · Marutani et al., 1999 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Loss Of Function	2	submitted	EID9443 Fifty missense mutations identified in sporadic breast cancer were assessed for qualitative and quantitative changes in their ability to transactivate from 11 human promoter response elements in a yea… (full text at CIViC) PMID 20407015 · Jordan et al., 2010 · Open in CIViC	civic

TP53 C238Y2
(functional)	—UNRESOLVED	Functional	D	Supports Dominant Negative	2	accepted	EID7215 This study evaluated the dominant negative potential of 103 p53 germline mutations contained in the IRAC database. The C238Y variant was considered severely deficient as cotransformation with empty ve… (full text at CIViC) PMID 21343334 · Monti et al., 2011 · Open in CIViC	civic
(prognostic)	Malignant Breast Neoplasm	Prognostic	E	Supports Poor Outcome	3	accepted	EID7173 Cys-238 was directly bound to zinc molecule. Patients with missense mutations affecting amino acids directly involved in DNA or zinc binding displayed a very aggressive clinical phenotype. When patien… (full text at CIViC) PMID 11051239 · Alsner et al., 2000 · Open in CIViC	civic

TP53 C242F2
(functional)	—UNRESOLVED	Functional	D	Supports Loss Of Function	3	submitted	EID13191 In matched biopsy and surgical specimens from a patient with lung squamous cell carcinoma, split FASAY identified TP53 C242F (codon 242 TGC>TTC). The mutant-containing 3′ fragment from the biopsy samp… (full text at CIViC) PMID 15161705 · Fouquet et al., 2004 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Loss Of Function	2	accepted	EID9451 Fifty missense mutations identified in sporadic breast cancer were assessed for qualitative and quantitative changes in their ability to transactivate from 11 human promoter response elements in a yea… (full text at CIViC) PMID 20407015 · Jordan et al., 2010 · Open in CIViC	civic